Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Lowers Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst James Quigley has maintained an Equal-Weight rating on Kymera Therapeutics (NASDAQ:KYMR) but lowered the price target from $39 to $37.
August 29, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Kymera Therapeutics but lowered the price target from $39 to $37.
The lowering of the price target by Morgan Stanley could potentially lead to a decrease in the stock price of Kymera Therapeutics in the short term as it indicates a lower valuation of the company by the analyst.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100